text: Teicoplanin is marketed by Sanofi-Aventis under the trade name Targocid. Other trade names include Ticocin marketed by  Cipla(India).
  Oral teicoplanin has been demonstrated to be effective in the treatment of pseudomembranous colitis and Clostridium difficile-associated diarrhoea, with comparable efficacy with vancomycin.
  Its strength is considered to be due to the length of the hydrocarbon chain.
  Teicoplanin is produced by the so-called "rare" actinobacterium Actinoplanes teichomyceticus ATCC 31121, belonging to the Micromonosporaceae family. Biosynthetic pathway leading to teicoplanin, as well as the regulatory circuit governing the biosynthesis, were studied intensively in recent years allowing to construct an integrated model of the biosynthesis.
  Indications
  Teicoplanin is applicable in treatment of a wide range of infections with Gram-positive bacteria, including endocarditis, septicaemia, soft tissue and skin infections, and venous catheter-associated infections.
  Susceptible organisms
  Teicoplanin has demonstrated in vitro efficacy against Gram-positive bacteria including staphylococci (including MRSA), streptococci, enterococci, and against anaerobic Gram-positive bacteria including Clostridium spp. Teicoplanin is not effective against Gram-negative bacteria as the large, polar molecules of the compound are unable to pass through the external membrane of these organisms.
  The following represents MIC susceptibility data for a few medically significant pathogens:
  Clostridium difficile: 0.06 μg/ml - 0.5 μg/ml
  Staphylococcus aureus: ≤0.06 μg/ml - ≥128 μg/ml
  Staphylococcus epidermidis: ≤0.06 μg/ml - 32 μg/ml